E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 12/30/2019 in the Prospect News Private Placement Daily.

Oncology Pharma settles $38.4 million financing with SCP Investment

By Devika Patel

Knoxville, Tenn., Dec. 30 – Oncology Pharma, Inc. secured a $38.4 million financing from SCP Investment Partners, Ltd., UK, according to a press release.

Proceeds will be used to complete licensing agreements with Kalos Therapeutics for its lead anti-cancer biopharmaceutical medication, KTH-222.

Based in San Francisco, Oncology Pharma researches cancer therapies.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.